Drug intelligence / Profile preview

Golvatinib

Development stage: Phase 2
Lead developer: Eisai
Modality: Small Molecules
Administration: Oral

Overview

Golvatinib is an investigational small molecule receptor tyrosine kinase inhibitor. It primarily targets the MET (hepatocyte growth factor receptor) and VEGFR2 (vascular endothelial growth factor receptor 2) pathways, both of which are implicated in tumor angiogenesis and cancer cell proliferation. Golvatinib was developed for the treatment of various solid tumors, including gastric cancer and head and neck squamous cell carcinoma. The drug was originally developed by Eisai.

Brand names: golvatinib
Other names: E7050E-7050E 7050golvatinib

Targets

MET (Mesenchymal-epithelial transition factor receptor)MST1R (Recepteur d'origine nantais)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)EPH (EPH receptor family)

Beyond the preview

Go deeper on Golvatinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Golvatinib.

Explore the full profile